Pharma: Clinic Roundup
Tuesday, March 13, 2012
Pfizer Inc., of New York, said data from a Phase III study of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) met all endpoints, showing immunogenicity and establishing a safety profile in children and adolescents, ages 5 through 17.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.